GMAB – Genmab A/S
Genmab A/SGMAB
$22.11Name : Genmab A/S
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $13,751,359,488.00
EPSttm : 1.7
Genmab A/S
$22.11
1.38%$0.3Float Short %
0.45
Margin Of Safety %
34
Put/Call OI Ratio
1.03
EPS Next Q Diff
0.12
EPS Last/This Y
-0.36
EPS This/Next Y
0.3
Price
21.81
Target Price
30.73
Analyst Recom
1.75
Performance Q
-8.01
Relative Volume
0.44
Beta
0.95
Ticker: GMAB
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-05-07 | GMAB | 20.58 | 0.58 | 6.00 | 17803 |
| 2025-05-08 | GMAB | 19.42 | 0.58 | 3.00 | 17802 |
| 2025-05-09 | GMAB | 19.37 | 0.59 | 999.99 | 17864 |
| 2025-05-12 | GMAB | 19.95 | 0.58 | 78.00 | 17842 |
| 2025-05-13 | GMAB | 19.32 | 0.58 | 62.02 | 17828 |
| 2025-05-14 | GMAB | 19.08 | 0.82 | 102.50 | 20622 |
| 2025-05-15 | GMAB | 19.66 | 0.82 | 0.13 | 20654 |
| 2025-05-16 | GMAB | 19.88 | 0.82 | 53.90 | 20641 |
| 2025-05-19 | GMAB | 20.17 | 1.55 | 0.03 | 3512 |
| 2025-05-20 | GMAB | 20.34 | 1.55 | 1.91 | 3516 |
| 2025-05-21 | GMAB | 20.51 | 1.54 | 100.10 | 3523 |
| 2025-05-22 | GMAB | 21.01 | 1.18 | 0.08 | 3040 |
| 2025-05-23 | GMAB | 20.81 | 1.17 | 0.00 | 3051 |
| 2025-05-27 | GMAB | 21.27 | 1.16 | 4.00 | 3062 |
| 2025-05-28 | GMAB | 21.2 | 1.16 | 1.50 | 3066 |
| 2025-05-29 | GMAB | 21.34 | 1.16 | 0.00 | 3068 |
| 2025-05-30 | GMAB | 20.97 | 1.16 | 1.33 | 3068 |
| 2025-06-02 | GMAB | 21.77 | 1.16 | 0.19 | 3073 |
| 2025-06-03 | GMAB | 21.35 | 1.02 | 7.33 | 3335 |
| 2025-06-04 | GMAB | 21.78 | 1.03 | 1.76 | 3361 |
| 2025-06-05 | GMAB | 21.8 | 1.03 | 1.36 | 3395 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-05-07 | GMAB | 20.60 | -21.4 | -99.3 | 1.38 |
| 2025-05-08 | GMAB | 19.42 | -21.4 | -164.3 | 1.38 |
| 2025-05-09 | GMAB | 19.38 | -21.4 | -72.3 | 1.38 |
| 2025-05-12 | GMAB | 19.93 | -21.4 | -16.0 | 1.38 |
| 2025-05-13 | GMAB | 19.31 | -21.4 | -95.7 | 1.38 |
| 2025-05-14 | GMAB | 19.08 | 22.6 | 353.4 | 1.36 |
| 2025-05-15 | GMAB | 19.66 | 22.6 | 15.7 | 1.36 |
| 2025-05-16 | GMAB | 19.88 | 30.2 | 36.3 | 1.57 |
| 2025-05-19 | GMAB | 20.18 | 30.2 | 44.3 | 1.57 |
| 2025-05-20 | GMAB | 20.33 | 30.2 | 57.5 | 1.57 |
| 2025-05-21 | GMAB | 20.51 | 30.2 | 22.0 | 1.57 |
| 2025-05-22 | GMAB | 21.02 | 18.0 | 82.6 | 1.40 |
| 2025-05-23 | GMAB | 20.80 | 18.0 | -14.4 | 1.40 |
| 2025-05-27 | GMAB | 21.28 | 5.9 | 74.3 | 1.34 |
| 2025-05-28 | GMAB | 21.21 | 5.9 | 23.2 | 1.34 |
| 2025-05-29 | GMAB | 21.34 | 5.9 | 91.0 | 1.34 |
| 2025-05-30 | GMAB | 20.95 | 5.9 | 62.2 | 1.34 |
| 2025-06-02 | GMAB | 21.77 | 5.9 | 80.0 | 1.34 |
| 2025-06-03 | GMAB | 21.35 | 5.9 | 45.6 | 1.34 |
| 2025-06-04 | GMAB | 21.77 | 5.9 | 64.6 | 1.34 |
| 2025-06-05 | GMAB | 21.81 | 5.9 | 26.8 | 1.34 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-05-07 | GMAB | 0 | 0.69 | 0.33 |
| 2025-05-08 | GMAB | 0 | 0.69 | 0.33 |
| 2025-05-09 | GMAB | 0 | 0.69 | 0.33 |
| 2025-05-12 | GMAB | 0 | 0.67 | 0.39 |
| 2025-05-13 | GMAB | 0 | 0.67 | 0.39 |
| 2025-05-14 | GMAB | 0 | 0.67 | 0.39 |
| 2025-05-15 | GMAB | 0 | 0.67 | 0.39 |
| 2025-05-16 | GMAB | 0 | 0.67 | 0.39 |
| 2025-05-19 | GMAB | 0 | -0.02 | 0.39 |
| 2025-05-20 | GMAB | 0 | -0.02 | 0.39 |
| 2025-05-21 | GMAB | 0 | -0.02 | 0.39 |
| 2025-05-22 | GMAB | 0 | -0.02 | 0.39 |
| 2025-05-23 | GMAB | 0 | -0.02 | 0.39 |
| 2025-05-27 | GMAB | 0 | -0.08 | 0 |
| 2025-05-28 | GMAB | 0 | -0.08 | 0.45 |
| 2025-05-29 | GMAB | 0 | -0.08 | 0.45 |
| 2025-05-30 | GMAB | 0 | -0.08 | 0.45 |
| 2025-06-02 | GMAB | 0 | -0.10 | 0.45 |
| 2025-06-03 | GMAB | 0 | -0.10 | 0.45 |
| 2025-06-04 | GMAB | 0 | -0.10 | 0.45 |
| 2025-06-05 | GMAB | 0 | -0.10 | 0.45 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.31
Avg. EPS Est. Current Quarter
0.34
Avg. EPS Est. Next Quarter
0.43
Insider Transactions
Institutional Transactions
-0.1
Beta
0.95
Average Sales Estimate Current Quarter
5951
Average Sales Estimate Next Quarter
6288
Fair Value
29.24
Quality Score
100
Growth Score
100
Sentiment Score
59
Actual DrawDown %
55.6
Max Drawdown 5-Year %
-63.1
Target Price
30.73
P/E
12.37
Forward P/E
12.21
PEG
1.35
P/S
4.15
P/B
2.62
P/Free Cash Flow
11.51
EPS
1.76
Average EPS Est. Cur. Y
1.34
EPS Next Y. (Est.)
1.64
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
35.11
Relative Volume
0.44
Return on Equity vs Sector %
-3.3
Return on Equity vs Industry %
14.6
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.04
EBIT Estimation
26.8
Genmab A/SSector: Healthcare
Industry: Biotechnology
Employees: 2638
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
stock quote shares GMAB – Genmab A/S Stock Price stock today
news today GMAB – Genmab A/S stock forecast ,stock prediction 2023 2024 2025
marketwatch GMAB – Genmab A/S yahoo finance google finance
stock history GMAB – Genmab A/S invest stock market
stock prices GMAB premarket after hours
ticker GMAB fair value insiders trading